Home

NASDAQ:XRTX Stock Quote

0.9700
+0.0100 (1.04%)

Xortx Therapeutics Inc is a biotechnology company dedicated to developing innovative therapies for kidney-related conditions, particularly focused on diseases such as chronic kidney disease and metabolic disorders

The company aims to address significant unmet medical needs by advancing its proprietary drug candidates through clinical trials and bringing novel solutions to patients suffering from these challenging health issues. By leveraging advancements in science and technology, Xortx is committed to improving the quality of life for individuals impacted by kidney diseases.

SummaryNewsPress ReleasesChartHistoricalFAQ
XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
New York, NY - March 19, 2024 - In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage clinical pharmaceutical firm specializing in revolutionary treatments for progressive kidney disease, has made headlines with its tremendous progress.
Via Get News · March 19, 2024
XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
New York, NY, March 19, 2024 – (Plato Data) -- In the realm of pharmaceutical innovation, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), stands out for its significant achievements in 2023 and ambitious plans for 2024. XORTX, a late-stage clinical pharmaceutical firm specializing in revolutionary treatments for progressive kidney disease, has made headlines with its tremendous progress.
Via TheNewswire.com · March 19, 2024